EMEA-001075-PIP04-15-M07 - paediatric investigation plan
romosozumab
PIPHuman
Estonian is available via eTranslation, the European Commission's machine translation service.
Translate to Estonian | Important information about machine translation
Key facts
- Invented name
- Evenity
- Active substance
- romosozumab
- Therapeutic area
- Musculoskeletal and connective tissue disorders
- Decision number
- P/0375/2024
- PIP number
- EMEA-001075-PIP04-15-M07
- Pharmaceutical form(s)
- Solution for injection
- Condition(s) / indication(s)
- Treatment of osteoporosis
- Route(s) of administration
- Subcutaneous use
- Contact for public enquiries
UCB Pharma S.A.
E-mail: UCBCares.UK@ucb.com
Tel: +44 (0)1753777100- Decision type
- PM: decision on the application for modification of an agreed PIP
- Decision date
- Compliance check done
- Ei